Genomics4S

As genomic technologies move from treating disease to selecting future individuals, definitions of disease cease to function exclusively as medical categories and become social decisions about which traits and what kinds of people should exist.

While the recent adoption of a flexible clinical translation model in Hainan Province promises to accelerate biomedical innovation in China, it has also intensified concerns about patient safety, transparency, and misinformation. The success of this new approach is largely dependent on strengthening post-market oversight, access to clinical data, and strategic alignment with international bioethical guidelines.

The global AI in clinical trials market, valued at US$1.20 billion in 2023, is projected to grow at a 12.4% annually, reaching US$2.74 billion by 2030. As AI reshapes how patients are identified, matched, and enrolled in clinical research, regulatory frameworks must evolve to address the structural diversity, data flows, and ethical risks embedded in these emerging platforms.

With the advent of AI in healthcare, expertise and experiences accrued in ethics oversight of other controversial fields of biomedical...